142 related articles for article (PubMed ID: 30269573)
21. Weight changes during clozapine treatment.
Briffa D; Meehan T
Aust N Z J Psychiatry; 1998 Oct; 32(5):718-21. PubMed ID: 9805596
[TBL] [Abstract][Full Text] [Related]
22. Weight gain among patients on clozapine.
Bai YM; Lin CC; Chen JY; Lin CY
Psychiatr Serv; 1999 May; 50(5):704-5. PubMed ID: 10332914
[No Abstract] [Full Text] [Related]
23. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain.
Reynolds GP; Zhang Z; Zhang X
Am J Psychiatry; 2003 Apr; 160(4):677-9. PubMed ID: 12668355
[TBL] [Abstract][Full Text] [Related]
24. Should obesity be a limiting factor for clozapine treatment?
Pons i Villanueva A; Romero A; Goti J; Fernandez-Egea E; Undurraga J; Carne X; Bernardo M
Rev Psiquiatr Salud Ment; 2013; 6(2):75-9. PubMed ID: 23084801
[TBL] [Abstract][Full Text] [Related]
25. A prospective study of serum ghrelin levels in patients treated with clozapine.
Theisen FM; Gebhardt S; Brömel T; Otto B; Heldwein W; Heinzel-Gutenbrunner M; Krieg JC; Remschmidt H; Tschöp M; Hebebrand J
J Neural Transm (Vienna); 2005 Oct; 112(10):1411-6. PubMed ID: 15959857
[TBL] [Abstract][Full Text] [Related]
26. Investigation of the Gut Microbiome in Patients with Schizophrenia and Clozapine-Induced Weight Gain: Protocol and Clinical Characteristics of First Patient Cohorts.
Gorbovskaya I; Kanji S; Liu JCW; MacKenzie NE; Agarwal SM; Marshe VS; Sriretnakumar V; Verdu EF; Bercik P; De Palma G; Hahn MK; Müller DJ
Neuropsychobiology; 2020; 79(1):5-12. PubMed ID: 30928978
[TBL] [Abstract][Full Text] [Related]
27. N-desmethylclozapine, an insensitive marker of clozapine-induced agranulocytosis and granulocytopenia.
Combs MD; Perry PJ; Bever KA
Pharmacotherapy; 1997; 17(6):1300-4. PubMed ID: 9399615
[TBL] [Abstract][Full Text] [Related]
28. Treatment of clozapine-associated weight gain: a systematic review.
Whitney Z; Procyshyn RM; Fredrikson DH; Barr AM
Eur J Clin Pharmacol; 2015 Apr; 71(4):389-401. PubMed ID: 25627831
[TBL] [Abstract][Full Text] [Related]
29. HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.
Ma X; Maimaitirexiati T; Zhang R; Gui X; Zhang W; Xu G; Hu G
Int J Psychiatry Clin Pract; 2014 Oct; 18(4):229-42. PubMed ID: 25152019
[TBL] [Abstract][Full Text] [Related]
30. Clozapine and weight gain.
Theisen FM; Cichon S; Linden A; Martin M; Remschmidt H; Hebebrand J
Am J Psychiatry; 2001 May; 158(5):816. PubMed ID: 11329412
[No Abstract] [Full Text] [Related]
31. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.
Smith RC; Maayan L; Wu R; Youssef M; Jing Z; Sershen H; Szabo V; Meyers J; Jin H; Zhao J; Davis JM
Psychopharmacology (Berl); 2018 Dec; 235(12):3545-3558. PubMed ID: 30382354
[TBL] [Abstract][Full Text] [Related]
32. [A patient on clozapine in the general hospital: the need for discussion between specialists from different disciplines and for close monitoring of the patient's plasma level].
van Zuilekom S; Gijsman HJ
Tijdschr Psychiatr; 2013; 55(12):955-9. PubMed ID: 24366834
[TBL] [Abstract][Full Text] [Related]
33. Cognitive behavior therapy for weight gain.
Umbricht D; Flury H; Bridler R
Am J Psychiatry; 2001 Jun; 158(6):971. PubMed ID: 11384925
[No Abstract] [Full Text] [Related]
34. Pharmacology of N-desmethylclozapine.
Lameh J; Burstein ES; Taylor E; Weiner DM; Vanover KE; Bonhaus DW
Pharmacol Ther; 2007 Aug; 115(2):223-31. PubMed ID: 17583355
[TBL] [Abstract][Full Text] [Related]
35. Predicting Weight Gain in Patients Treated With Clozapine: The Role of Sex, Body Mass Index, and Smoking.
Lau SL; Muir C; Assur Y; Beach R; Tran B; Bartrop R; McLean M; Caetano D
J Clin Psychopharmacol; 2016 Apr; 36(2):120-4. PubMed ID: 26872115
[TBL] [Abstract][Full Text] [Related]
36. Importance of oral glucose tolerance test in patient with schizophrenia.
Margetić B; Aukst-Margetić B; Badanjak A
Psychiatr Danub; 2005 Jun; 17(1-2):94-6. PubMed ID: 16395850
[TBL] [Abstract][Full Text] [Related]
37. A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses.
Kelly AC; Sheitman BB; Hamer RM; Rhyne DC; Reed RM; Graham KA; Rau SW; Gilmore JH; Perkins DO; Peebles SS; VanderZwaag CJ; Jarskog LF
J Clin Psychopharmacol; 2014 Aug; 34(4):441-5. PubMed ID: 24943389
[TBL] [Abstract][Full Text] [Related]
38. Novel antipsychotics: comparison of weight gain liabilities.
Wirshing DA; Wirshing WC; Kysar L; Berisford MA; Goldstein D; Pashdag J; Mintz J; Marder SR
J Clin Psychiatry; 1999 Jun; 60(6):358-63. PubMed ID: 10401912
[TBL] [Abstract][Full Text] [Related]
39. Novel versus conventional antipsychotic drugs.
Love RC
Pharmacotherapy; 1996; 16(1 Pt 2):6-10. PubMed ID: 8778684
[TBL] [Abstract][Full Text] [Related]
40. Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining?
Remington G
Am J Psychiatry; 2006 Jul; 163(7):1132-4. PubMed ID: 16816213
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
